Therapy of sickle cell disease: an approach with sodium cyanate.
D000284:Administration, Oral; D000755:Anemia, Sickle Cell / Q000188:drug therapy*; D000818:Animals; D001663:Bilirubin / Q000097:blood; D002219:Carbamates / Q000096:biosynthesis; D003485:Cyanates / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004285:Dogs; D004912:Erythrocytes / Q000378:metabolism; D000882:Haplorhini; D006801:Humans; D051379:Mice; D010101:Oxygen Consumption; D010455:Peptides / Q000378:metabolism; D051381:Rats; D012964:Sodium / Q000627:therapeutic use*
D002219:Carbamates; D003485:Cyanates; D010455:Peptides; D012964:Sodium; D001663:Bilirubin